Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ironwood Pharmaceuticals

0.7267
-0.0233-3.11%
Post-market: 0.72670.00000.00%19:44 EDT
Volume:3.33M
Turnover:2.47M
Market Cap:117.59M
PE:131.39
High:0.7801
Open:0.7492
Low:0.7002
Close:0.7500
Loading ...

Ironwood Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
08 Nov 2024

Stock Track | Ironwood Pharmaceuticals Reports Disappointing Q3 Results, Stock Plunges

Stock Track
·
07 Nov 2024

Stock Track | Ironwood Pharmaceuticals Misses Q3 Earnings Estimate, Outlook Maintained

Stock Track
·
07 Nov 2024

Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates

Zacks
·
07 Nov 2024

Ironwood: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

Ironwood Pharmaceuticals Continues To Expect 2024 Total Revenue Of $350M-$375M Vs. Consensus Of $357.181M

Benzinga
·
07 Nov 2024

Ironwood Pharmaceuticals Q3 2024 Adj. EPS $0.02 Misses $0.08 Estimate, Sales $91.592M Beat $91.248M Estimate

Benzinga
·
07 Nov 2024

BRIEF-Ironwood Pharmaceuticals Q3 Revenue USD 91.592 Million Vs. IBES Estimate USD 91.2 Million

Reuters
·
07 Nov 2024

Ironwood Pharmaceuticals Inc: Maintains Full Year 2024 Financial Guidance

THOMSON REUTERS
·
07 Nov 2024

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Business Wire
·
07 Nov 2024

Ironwood Says Apraglutide Shows 'Consistent Treatment Effect' in Short Bowel Syndrome; Shares Rise

MT Newswires Live
·
28 Oct 2024

Ironwood Pharmaceuticals Shares Rise 10% on Positive Results in Bowel Disease Study

Dow Jones
·
28 Oct 2024

BRIEF-Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics And Disease Characteristics In Adults With Short Bowel Syndrome With Intestinal Failure (Sbs-If), According To New Stars Phase Iii Data From Ironwood At Acg 2024

Reuters
·
28 Oct 2024

Ironwood to present new findings from STARS trial at ACG

TIPRANKS
·
28 Oct 2024

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults With Short Bowel Syndrome With Intestinal Failure (SBS-IF), According to New Stars Phase Iii Data From Ironwood at Acg 2024

THOMSON REUTERS
·
28 Oct 2024

Ironwood: Expects to Complete U.S. Regulatory Submission in Q1 2025

THOMSON REUTERS
·
28 Oct 2024

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Business Wire
·
28 Oct 2024